Patient Satisfaction with Oral Testosterone Undecanoate in Men Who Received Prior Testosterone Therapy: An Open-Label, Single-Center Clinical Trial.

Rivero, Marco-Jose; Reddy, Rohit; Muthigi, Akhil; Reddy, Raghuram; Han, Sunwoo; Reis, Isildinha M; Patel, Mehul; Ramasamy, Ranjith

Rivero, Marco-Jose; Reddy, Rohit; Muthigi, Akhil; Reddy, Raghuram; Han, Sunwoo; Reis, Isildinha M; Patel, Mehul; Ramasamy, Ranjith.

Afiliação

Rivero MJ; Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
Reddy R; Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
Muthigi A; Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
Reddy R; Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA.
Han S; Biostatistics and Bioinformatics Shared Resource, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Reis IM; Biostatistics and Bioinformatics Shared Resource, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Patel M; Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.
Ramasamy R; Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL, USA.

World J Mens Health ; 2024 Jan 02.

Article em En | MEDLINE | ID: mdl-38164037

ABSTRACT

ABSTRACT

PURPOSE:

To evaluate patient satisfaction and symptom control in hypogonadal men transitioning from other testosterone therapies to oral testosterone undecanoate (TU). MATERIALS AND

METHODS:

In this open-label clinical trial, men aged 18 to 75 years with hypogonadism were switched to oral TU after a sufficient washout of previous testosterone therapies. Treatment satisfaction and symptom control were primarily measured using the 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9) and quantitative androgen deficiency in aging males (qADAM) questionnaires, respectively. Secondary outcomes included changes in serum testosterone (T), estradiol (E2), hematocrit (HCT), and prostate-specific antigen (PSA) levels.

RESULTS:

Forty-one men participated, with significant improvements in all TSQM-9 scores observed over 6 months. Symptom control as measured by qADAM remained consistent. There was a significant increase in serum T and E2 levels, but HCT and PSA levels remained stable.